home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

8th Annual ImVacS: The Immunotherapeutics and Vaccine Summit

 
  April 29, 2013  
     
 
Hilton Boston Back Bay, 40 Dalton Street, Boston, MA 02115
August 13-15, 2013


August 13:

  • INFLUENZA

    • The Compelling Need for Game-Changing Influenza Vaccines
    • Toward a Universal Influenza Virus Vaccine
    • Flublok, the First FDA Approved Recombinant Influenza Vaccine
    • Cell Culture-Based Influenza Vaccine, Current and Future Prospects
    • New Influenza Vaccines; This Should Be Easy!
  • CONQUERING DISEASE

    • TB Vaccine Development
    • Staphylococcus Vaccine Development
    • GeoVax Aids Vaccine, Progress towards Prevention of Infection
    • Development of a Novel Vaccine for the Prevention of Clostridium difficile Infection
    • Panel Discussion:  Strategies to Develop Efficacious Influenza Vaccines

August 14:

  • ADJUVANTS

    • Adjuvants: Yesterday, Today and Tomorrow
    • Making a "Super" Vaccine: Using TNF Superfamily Ligands to Adjuvant Antibody and T Cell Responses from HIV-1 DNA and Viral Vector Vaccines
    • Inducing Broadly Cross-Protective Antiviral Immunity with Advax, a 3rd Generation Vaccine Adjuvant
    • Improving the Efficacy of Cancer and Infectious Disease Vaccines with the Novel Synthetic Saponin Adjuvants
    • Development of Cyclic Dinucleotides (CDNs) as STING-Targeted Molecular Adjuvants
    • Development of Protein Capsular Matrix Vaccine (PCMV) Platform Technology
  • DNA VACCINES

    • New Insight on the Induction of High Quality Antibody Responses by DNA Immunization
    • Turning Self-Destructing Salmonella into a Universal DNA Vaccine Delivery Platform for Prevention and Treatment of a Diversity of Diseases
    • Novel HIV Vaccine Strategies
  • ANTIGEN INSIGHTS

    • A Microbial Achilles Heel: Poly-N-acetyl Glucosamine is a Ubiquitously Expressed Vaccine Target on Bacterial, Fungal and Protozoan Pathogens
    • Breast Cancer Vaccines Targeting the Thomsen- Friedenreich Antigen
    • Single vs. Multiple Antigens

August 15: 

  • NEW TECHNOLOGIES AND APPROACHES FOR DEVELOPING VACCINES

    • Systematic Dissection of Immune Responses in Humans by Utilizing Natural Variations and Vaccination
    • Novel AIDS Vaccine Approaches: Focus on Epitopes Linked to Vaccine Protection
    • Developing mRNA-Vaccine Technologies
    • Adjuvant-Guidance of T Cell Responses
    • Fungal Antigens that Protect Against Fungal and Bacterial Pathogens
    • Development of Thermostable Vaccine Formulations
  • PARTICLE TECHNOLOGY

    • Skin Delivery of Flu Vaccine with Micro Arrays
    • Tuning Innate Immune Activation by Surface Texturing of Polymer Microparticles: The Role of Shape in Inflammasome Activation
    • Replicating Adenovirus Serotype 4 Vector Vaccine for H5N1 Influenza: Phase I Clinical Study Results and Proof-of-Concept
    • The Versatile Utility of Biodegradable Particles in Vaccinations
    • Targeted Tolerogenic Synthetic Vaccine Particles (t2SVP) for the Treatment of Allergies, Autoimmune Diseases and Orphan Diseases
 
 
Organized by: Cambridge Healthtech Institute
Invited Speakers:
  • Michael T. Osterholm, Ph.D., MPH, Director, Center for Infectious Disease Research and Policy (CIDRAP), Professor, Environmental Health Sciences, School of Public Health, University of Minnesota
  • Peter Palese, Ph.D., Horace W. Goldsmith Professor and Chair, Microbiology, Professor, Department of Medicine, Icahn School of Medicine at Mount Sinai
  • Manon Cox, Ph.D., CEO, Protein Sciences
  • Theodore Tsai, Ph.D., Senior Vice President, Scientific Affairs, Novartis Vaccines
  • Alan Shaw, Ph.D., President and CEO, Vedantra
  • Jerald Sadoff, M.D., Head, Early Development, Crucell Vaccine Institute
  • Amita Joshi, Ph.D., Senior Research Immunologist, Merck & Co., Inc.
  • Harriet Robinson, Ph.D., CSO, GeoVax Labs, Inc.
  • Jon Heinrichs, Ph.D., Director, Microbial Vaccines, Vaccines Research, Merck & Co., Inc.
  • William M. Egan, Ph.D., Senior Tech Expert, Novartis Vaccines & Diagnostics, Inc.
  • Nathalie Garçon, Ph.D., Vice President and Head, Global Center for Adjuvants and Technology Innovation, GlaxoSmithKline Biologicals
  • Geoffrey Stone, Ph.D., Assistant Professor, Microbiology, and Group Leader, Immmunology, HIV Immunotherapy Program, University of Miami Miller School of Medicine
  • Nikolai Petrovsky, Ph.D., Professor, Endocrinology Department, Flinders Medical Centre, Flinders University, and Research Director, Vaxine Pty Ltd.
  • Jeffrey Gardner, CEO, Executive, Adjuvance Technologies, Inc.
  • Thomas Dubensky, Ph.D., CSO, Research and Development, AduroBioTech, Inc.
  • Kevin P. Killeen, Ph.D., Vice President, Research & Business Development, Matrivax Research & Development Corp.
  • Shan Lu, M.D., Ph.D., Professor, Infectious Diseases and Immunology, University of Massachusetts Medical School
  • Wei Kong, Ph.D., Research Assistant Professor, Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University
  • Dan H. Barouch, M.D., Ph.D., Associate Professor, Medicine, Chief, Division of Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center
  • Gerald Pier, Ph.D., Professor, Medicine, Microbiology and Immunobiology, Harvard Medical School
  • Kate Rittenhouse-Olson, Ph.D., Professor and Director, Biotechnology Program, Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo
  • Graham J. Clarke, CEO & Director, ImmunoBiology, Ltd.
  • John Tsang, Ph.D., Chief, Systems Genomics and Bioinformatics Unit, LSB, Head, Computational Systems Biology, Trans-NIH Center for Human Immunology (CHI), NIAID-NIH
  • Ruth M. Ruprecht, M.D., Ph.D., Professor of Medicine, Harvard Medical School and the Dana-Farber Cancer Institute
  • Karl-Josef Kallen, M.D., Ph.D., CSO, CureVac GmbH
  • Magdalena Tary-Lehmann, M.D., Ph.D., CSO, Cellular Technology Limited (C.T.L.)
  • John P. Hennessey, Jr., Ph.D., Vice President, Novadigm Therapeutics, Inc.
  • Alex Flood, Ph.D., Program Officer, Technology Solutions, PATH
  • Derek O'Hagan, Ph.D., Global Head, Vaccine Delivery Research, Novartis Vaccines
  • Evelyn A. Kurt-Jones, Ph.D., Professor of Medicine, University of Massachusetts Medical School
  • Marc Gurwith, M.D., CMO, PaxVax
  • Aliasger K. Salem, Ph.D., Leader, Cancer Signalling and Experimental Therapeutics, Holden Comprehensive Cancer Center, Pharmaceutical Sciences and Experimental Therapeutics, Chemical and Biochemical Engineering and Biomedical Engineering, College of Pharmacy and Engineering, University of Iowa
  • Takashi Kishimoto, Ph.D., CSO, Selecta Biosciences
 
Deadline for Abstracts: July 19, 2013
 
Registration: Register Now
E-mail: kwaterman@healthtech.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.